Creative Medical Technology Holdings, Inc. filed a Form 8-K on November 13, 2026, disclosing that it received a Nasdaq deficiency notice on November 10, 2026, for failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.

Key Highlights

  • Deficiency notice received: Creative Medical Technology Holdings received a letter from The Nasdaq Stock Market on November 10, 2026, citing non-compliance with Nasdaq Listing Rule 5550(a)(2).
  • Trigger: The company's common stock closing bid price was below $1.00 per share for 30 consecutive business days, according to the filing.
  • No immediate listing impact: The filing states the notice "has no immediate impact on the Company's listing."
  • 180-day grace period: The company has until May 10, 2027, to regain compliance by achieving a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.
  • Possible extension: The company disclosed it may be eligible for an additional 180-day grace period if it meets Nasdaq's initial listing standards for The Nasdaq Capital Market, other than the minimum bid price requirement.
  • Company response: The filing states the company "intends to actively monitor the bid price" and "will consider available options to regain compliance."

Creative Medical Technology Discloses Nasdaq Minimum Bid Price Non-Compliance

According to the Form 8-K filed with the SEC on November 13, 2026, Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) received written notice from The Nasdaq Stock Market on November 10, 2026, informing the company that it was not in compliance with Nasdaq Listing Rule 5550(a)(2). The rule requires that listed securities maintain a closing bid price of at least $1.00 per share. The filing states the breach occurred because the company's common stock closing bid price fell below that threshold for 30 consecutive business days.

The filing notes the deficiency notice carries no immediate effect on the company's continued listing on Nasdaq. Under Nasdaq's rules, as described in the filing, the company has a 180-day grace period running until May 10, 2027. To regain compliance within that window, the company's common stock bid price must close at $1.00 per share or more for a minimum of ten consecutive business days. The company may also qualify for a second 180-day grace period, provided it satisfies Nasdaq's initial listing standards for The Nasdaq Capital Market in all respects except the minimum bid price requirement.

The 8-K was signed by Timothy Warbington, Chief Executive Officer, on behalf of the registrant. The company disclosed that it "intends to actively monitor the bid price for its common stock between now and May 10, 2027, and will consider available options to regain compliance with the Nasdaq minimum bid price requirements." No specific remediation steps were enumerated in the filing.

What Was Disclosed

Creative Medical Technology Holdings, Inc. disclosed receipt of a Nasdaq non-compliance notice under Listing Rule 5550(a)(2) due to its common stock closing bid price remaining below $1.00 for 30 consecutive business days, with a compliance deadline of May 10, 2027.